Synthego, a supplier of CRISPR solutions, has entered a strategic licensing agreement with AstraZeneca. Through the agreement, Synthego is granted a global license to manufacture and distribute AstraZeneca’s novel CRISPR gene editing enzyme, eSpOT-ON, recently published as engineered ePsCas9, to the worldwide research community. The nuclease developed by AstraZeneca will be paired with Synthego’s gRNA to enable improved health outcomes.

Under the terms of the agreement, Synthego also receives exclusive commercialisation rights including the right to sublicense this nuclease for therapeutic and commercial use.